Genomisch onderzoek kan duizenden borstkankerpatiënten chemotherapie besparen

Researchers have developed a genomic test that could enable thousands of breast cancer patients to forgo chemotherapy while maintaining treatment effectiveness. The OPTIMA trial, involving over 4,400 patients with hormone receptor-positive, HER2-negative early breast cancer, demonstrated that this genetic screening approach can safely guide treatment decisions for the most common breast cancer